Townsend Asset Management’s AbbVie ABBV Stock Holding History

Townsend Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Buy	1,065 +29	+3%	+$6.24K	0.09%	122
2026 Q1	$225K	Sell	1,036 -3	-0.3%	-$665	0.08%	124
2025 Q4	$237K	Sell	1,039 -35	-3%	-$7.97K	0.08%	113
2025 Q3	$249K	Buy	+1,074	New	+$219K	0.09%	108
2025 Q2	–	Sell	-1,364	Closed	-$286K	–	178
2025 Q1	$286K	Buy	1,364 +3	+0.2%	+$583	0.11%	103
2024 Q4	$242K	Sell	1,361 -93	-6%	-$17.1K	0.09%	116
2024 Q3	$287K	Buy	1,454 +1	+0.1%	+$187	0.11%	113
2024 Q2	$249K	Buy	1,453 +2	+0.1%	+$331	0.1%	117
2024 Q1	$264K	Buy	1,451 +156	+12%	+$26.9K	0.11%	118
2023 Q4	$201K	Sell	1,295 -98	-7%	-$14.3K	0.09%	123
2023 Q3	$208K	Buy	+1,393	New	+$204K	0.1%	116
2023 Q2	–	Sell	-1,399	Closed	-$223K	–	202
2023 Q1	$223K	Sell	1,399 -118	-8%	-$18K	0.12%	125
2022 Q4	$245K	Buy	+1,517	New	+$233K	0.12%	125
2022 Q3	–	Sell	-1,414	Closed	-$217K	–	193
2022 Q2	$217K	Sell	1,414 -5	-0.4%	-$764	0.11%	135
2022 Q1	$230K	Buy	+1,419	New	+$206K	0.11%	130

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Townsend Asset Management's ABBV Position: Q2 2026 in Review

Townsend Asset Management increased its AbbVie (ABBV) stake by 2.8% in Q2 2026, buying an estimated $6.24K and bringing the position to 1,065 shares worth $268K. The position accounts for 0.09% of the portfolio, ranked #122.

Townsend Asset Management first reported a position in ABBV in Q1 2022 and has held it in 15 quarters since. The position peaked at $287K in Q3 2024. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Townsend Asset Management held 1,065 shares of AbbVie worth $268K as of Q2 2026.
Townsend Asset Management bought 29 AbbVie shares in Q2 2026, an estimated $6.24K.
AbbVie made up 0.09% of Townsend Asset Management's portfolio in Q2 2026, its #122 holding.
Townsend Asset Management first reported a position in AbbVie in Q1 2022 and has held it in 15 quarters since.
Townsend Asset Management's AbbVie position peaked at $287K in Q3 2024.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Townsend Asset Management's 13F filing for Q2 2026, filed 24 Jul 2026.